Видео ютуба по тегу Axitinib

Dr. Rini on Axitinib for Treatment of Metastatic Renal Cell Carcinoma
Dr. Rini on Axitinib for Treatment of Metastatic Renal Cell Carcinoma
KEYNOTE-426: Pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma
KEYNOTE-426: Pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma
Updated results of axitinib and nivolumab in previously treated mRCC
Updated results of axitinib and nivolumab in previously treated mRCC
Axitinib plus pembrolizumab in advanced RCC
Axitinib plus pembrolizumab in advanced RCC
NAXIVA: axitinib for reducing VTT in RCC
NAXIVA: axitinib for reducing VTT in RCC
Dr. Rini Discusses Pembrolizumab Plus Axitinib in mRCC
Dr. Rini Discusses Pembrolizumab Plus Axitinib in mRCC
Dr. Rini Describes Axitinib's and Sorafenib's Side Effects
Dr. Rini Describes Axitinib's and Sorafenib's Side Effects
Promising results for axitinib and pembrolizumab in advanced renal cell cancer
Promising results for axitinib and pembrolizumab in advanced renal cell cancer
Avelumab plus axitinib shows good efficacy for OS and PFS in aRCC patients
Avelumab plus axitinib shows good efficacy for OS and PFS in aRCC patients
Dr. Rini Explains the Axitinib Integration Process
Dr. Rini Explains the Axitinib Integration Process
Final results of avelumab and axitinib in RCC in the JAVELIN Renal 101 trial
Final results of avelumab and axitinib in RCC in the JAVELIN Renal 101 trial
Exciting potential of pembrolizumab combined with axitinib for kidney cancer
Exciting potential of pembrolizumab combined with axitinib for kidney cancer
Dr. Rini on Managing the Toxicity of Pembrolizumab Plus Axitinib in mRCC
Dr. Rini on Managing the Toxicity of Pembrolizumab Plus Axitinib in mRCC
Dr. Vaishampayan on Axitinib Plus Pembrolizumab in Advanced RCC
Dr. Vaishampayan on Axitinib Plus Pembrolizumab in Advanced RCC
Dr. Rini on the Efficacy of Axitinib and Pembrolizumab in RCC
Dr. Rini on the Efficacy of Axitinib and Pembrolizumab in RCC
Avelumab and axitinib vs sunitinib in treating advanced renal cell carcinoma
Avelumab and axitinib vs sunitinib in treating advanced renal cell carcinoma
Dr. Rini on Pembrolizumab Plus Axitinib in RCC
Dr. Rini on Pembrolizumab Plus Axitinib in RCC
Real-world efficacy of avelumab and axitinib in advanced renal cell carcinoma
Real-world efficacy of avelumab and axitinib in advanced renal cell carcinoma
Dr. Choueiri on Avelumab Plus Axitinib in mRCC
Dr. Choueiri on Avelumab Plus Axitinib in mRCC
Pembrolizumab monotherapy and pembro-axitinib for RCC
Pembrolizumab monotherapy and pembro-axitinib for RCC
Dr. Cella on the Side Effect Focus of the Axitinib and Sorafenib Trial
Dr. Cella on the Side Effect Focus of the Axitinib and Sorafenib Trial
Overview of a Phase III Trial of Pembrolizumab Plus Axitinib in RCC
Overview of a Phase III Trial of Pembrolizumab Plus Axitinib in RCC
Dr. Rini Discusses the VEGF Targeted Agent Axitinib
Dr. Rini Discusses the VEGF Targeted Agent Axitinib
AGILE Trial: Frontline Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma
AGILE Trial: Frontline Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma
Axitinib IS the New Standard of Care in 2nd-line: PRO Brian I. Rini, M.D.
Axitinib IS the New Standard of Care in 2nd-line: PRO Brian I. Rini, M.D.